As of today (2022-08-15), Merck's share price is $91.02.
Merck's Owner Earnings per Share (TTM) ended in Jun. 2022 was $5.52. It's Price-to-Owner-Earnings for today is 16.49.
The historical rank and industry rank for Merck's Price-to-Owner-Earnings or its related term are showing as below:
MRK'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.51 Med: 18.73 Max: 132.91
Current: 16.48
During the past 13 years, the highest Price-to-Owner-Earnings of Merck was 132.91. The lowest was 9.51. And the median was 18.73.
MRK's Price-to-Owner-Earnings is ranked better than 62.95% of 448
companies
in the Drug Manufacturers industry
Industry Median: 22.01
vs MRK: 16.48
As of today (2022-08-15), Merck's share price is $91.02.
Merck's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $6.53. Therefore, Merck's PE Ratio for today is 13.94.
As of today (2022-08-15), Merck's share price is $91.02.
Merck's EPS without NRI for the trailing twelve months (TTM) ended in was $6.56. Therefore, Merck's PE Ratio without NRI for today is 13.88.
During the past 13 years, Merck's highestPE Ratio without NRI was 118.22. The lowest was 12.61. And the median was 24.75.
Merck Price-to-Owner-Earnings Historical Data
The historical data trend for Merck's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Merck Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Price-to-Owner-Earnings
-
27.34
25.50
65.11
19.73
Merck Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Price-to-Owner-Earnings
131.37
43.98
19.73
17.64
16.51
Competitive Comparison
For the Drug Manufacturers - General subindustry, Merck's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck Price-to-Owner-Earnings Distribution
For the Drug Manufacturers industry and Healthcare sector, Merck's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Merck's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Merck's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Merck's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.09(2.35%) Volume: 9,374,968 8:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MRK has been successfully added to your 
